Trevi Therapeutics (TRVI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Serge Belanger from Needham maintained a Buy rating on the stock and has a $24.00 price target.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Serge Belanger has given his Buy rating due to a combination of factors surrounding Trevi Therapeutics’ promising developments. The recent data from the RIVER trial highlights Haduvio’s strong efficacy in treating RCC and IPF cough, which are areas with significant unmet medical needs. The trial results demonstrated that Haduvio effectively met its primary endpoint and showed favorable patient-reported outcomes, reinforcing its potential as a leading treatment option.
Moreover, the safety and tolerability profile of Haduvio was consistent with previous studies, with most adverse events occurring at the lowest dose. Key opinion leaders (KOLs) expressed optimism about Haduvio’s efficacy, noting that its performance in the CANAL and RIVER trials surpassed that of other treatment candidates. This positive feedback, coupled with the anticipation of upcoming trial results, supports the view that Haduvio could significantly impact the treatment landscape, justifying the Buy rating.
According to TipRanks, Belanger is a 2-star analyst with an average return of -0.1% and a 38.63% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Cytokinetics, Liquidia Technologies, and Trevi Therapeutics.
In another report released on May 12, Leerink Partners also reiterated a Buy rating on the stock with a $11.00 price target.